Letrozole (Femara)
Also known as: Femara, Letrozol, Letrozole, Letro
The most potent commonly used aromatase inhibitor — useful for acute gynecomastia, but far too strong for routine estradiol management.
Substance family
They block the enzyme that converts androgens to estrogens. The recurring error is using them without measuring — estradiol that is too low causes symptoms confusingly similar to estradiol that is too high.
Effects on
Which outcomes this substance acts on — descriptive, not a recommendation.
Strain profile
Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.
This substance causes
This substance works against
Dosing & protocols by goal
Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.
Breast cancer therapy (approved indication)
MedicalDose
2.5 mg / day
Frequency
1× daily
Cycle length
Ongoing, medically supervised
The approved use. The doses below are a fraction of this.
Acute gynecomastia
AdvancedDose
1.25–2.5 mg / day
Frequency
1× daily
Cycle length
7–14 days, then taper down
Short-term use when breast tissue is actively developing. Tamoxifen is often combined, since letrozole lowers estradiolestradiolThe main estrogen — needed in men too, and damaging in both directions when out of range. but does not block the receptor.
Estradiol management (not recommended)
AdvancedDose
0.25–0.5 mg / week
Frequency
1–2× / week
Cycle length
Only briefly
Letrozole is poorly suited to this. It crashes estradiolestradiolThe main estrogen — needed in men too, and damaging in both directions when out of range. easily; anastrozole or exemestane are far more controllable for routine management.
Side effect & countermeasure
Typical problems and what you can do to reduce harm — at a glance. Does not replace medical monitoring.
Problem
Estradiol crashed to near zero
Countermeasure
The defining risk. Letrozole can suppress estradiolestradiolThe main estrogen — needed in men too, and damaging in both directions when out of range. by more than 95 percent — far beyond what is wanted here. Joint pain, complete loss of libido, depressive mood and lethargy follow within days. Measure before and during; if in doubt, use a milder inhibitor.
Problem
Rebound after stopping
Countermeasure
As a reversible inhibitor, aromatase resumes work when the substance clears, and estradiolestradiolThe main estrogen — needed in men too, and damaging in both directions when out of range. can overshoot. Taper down rather than stopping abruptly; exemestane does not have this problem.
Problem
Worsening of the lipid profile
Countermeasure
Non-steroidal inhibitors tend to lower HDLHDLThe lipoprotein that carries cholesterol away from artery walls — suppressed hard by oral steroids. further — on top of what the cycle compounds already do. Cardio, omega-3, possibly citrus bergamot; keep the duration short.
Problem
Used for routine management instead of acute situations
Countermeasure
Letrozole is a tool for acute gynecomastiagynecomastiaGrowth of actual breast gland tissue in men — not fat, and not reversible once established., not for weekly estradiolestradiolThe main estrogen — needed in men too, and damaging in both directions when out of range. control. For that, anastrozole or exemestane are more controllable and far less likely to overshoot.
Problem
Effects on bone density with prolonged use
Countermeasure
Strong estrogen suppressionsuppressionThe body shutting down its own testosterone production because an external source is present. affects bone density in men too. Short courses only; not a substance for continuous use in this context.
Problem
Wrong tool for non-aromatizing compounds
Countermeasure
With trenbolone, oxymetholone or the DHTDHTA far more potent androgen the body makes from testosterone — responsible for hair loss and prostate effects. derivatives, an aromatase inhibitoraromatase inhibitorA drug that blocks the conversion of testosterone to estradiol. does not address the mechanism. Nipple symptoms there are progestogenicprogestogenicActing on the progesterone receptor — a property of 19-nor compounds that causes estrogen-like problems without high estradiol. or receptor-mediated — tamoxifen or cabergoline are the relevant options.
Overview
Letrozole is the most potent of the commonly used aromatase inhibitors. Where anastrozole suppresses estradiol by roughly seventy to eighty percent, letrozole reaches well over ninety-five percent.
That potency defines both its use and its problem. For an acute situation — breast tissue actively developing during a cycle — it is the strongest available tool. For everything else it is usually the wrong choice, because in this context the goal is not to eliminate estrogen but to keep it in the normal range.
Mechanism of Action
Letrozole binds reversibly to the aromatase enzyme and blocks the conversion of androgens to estrogens. Reversibly means the enzyme resumes work once the substance has cleared — which is the basis of the rebound effect after stopping.
The difference from anastrozole is one of degree, not mechanism. Both work the same way; letrozole simply binds more strongly and suppresses more completely. At the approved dose of two and a half milligrams, estradiol in men falls to barely measurable levels within days.
Estrogen at that level is not a neutral state. It is needed for lipid metabolism, bone density, libido, joint comfort and mood. The symptoms of a crash — dry painful joints, complete loss of libido, depressive mood, lethargy — are frequently mistaken for high estradiol, which leads people to increase the dose and make it considerably worse.
Non-steroidal inhibitors additionally tend to worsen the lipid profile, which matters in a context where the compounds being used already push HDL down.
Typical Context
The sensible application is acute: breast tissue that has started to develop and needs to be stopped quickly. Over one to two weeks at low doses, tapering down afterwards rather than stopping abruptly.
Tamoxifen is often combined here, and the reasoning is mechanical. Letrozole lowers the amount of estradiol; tamoxifen blocks the receptor at breast tissue. Tissue that has already begun to develop responds to the receptor blockade, which lowering the level alone does not achieve.
For routine estradiol management during a cycle, letrozole is a poor fit. It overshoots easily, and the difference between an effective and an excessive dose is small. Anastrozole or exemestane are far more controllable, and exemestane additionally avoids the rebound and the lipid effect.
Side Effects & Risks
- Estradiol crashed to near zero, with joint pain, loss of libido and depressive mood
- Rebound after abrupt discontinuation
- Worsening of the lipid profile (HDL drops further)
- Fatigue, lethargy
- Effects on bone density with prolonged use
- Headache, hot flushes
Blood Work & Monitoring
- Estradiol (sensitive) — essential here; letrozole is not a substance to dose blind
- Lipid profile (LDL, HDL, triglycerides) — non-steroidal inhibitors worsen it
- Total/free testosterone — for context
- Liver values (ALT, AST, GGT)
Harm-Reduction Notes
- Reserve it for acute gynecomastia; use anastrozole or exemestane for routine management
- Measure estradiol before and during — the margin between effective and excessive is narrow
- Taper down rather than stopping abruptly, to avoid the rebound
- Combine with tamoxifen when tissue has already developed; lowering the level alone does not reverse it
- Keep courses short; prolonged suppression affects bone density and lipids
- Not the right tool for non-aromatizing compounds
- Joint pain and lost libido mean too little estradiol, not too much
Legal status by region
Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.
| Region | Regulatory status |
|---|---|
| United States | Prescription-only medicineApproved for defined indications; use outside them is off-label. |
| EU / UK | Prescription-only medicineApproved for defined indications. |
| Canada / Australia | Prescription-only medicine |
| Parts of Asia, Latin America & Middle East | Pharmacy availability variesSeveral countries dispense it without prescription in practice. Rules and enforcement differ and change. |
| Competitive sport | Check the current WADA listSome substances in this class are prohibited, others are not. |